Inhalation Sciences: Full enrolment reached in landmark PreciseInhale clinical trial

Report this content

(Stockholm, Sweden, June 22, 2021) Full enrolment has been reached, on schedule, in ISAB’s clinical trial of its aerosol generating system PreciseInhale®- with all 12 patients recruited. CEO Manoush Masarrat: “Clinical validation would make PreciseInhale® the first aerosol generation platform that can be used from drug discovery, through preclinical studies, all the way to phase I clinical trials - a major milestone that could open up significant new markets.”

The first 4 healthy volunteer patients were enrolled on Wednesday 16 June. Now all 12 patients have been enrolled onto the study, which is being run by Clinical Trial Consultants AB (CTC), a CRO and clinical trial consultancy with test facilities adjacent to Uppsala University Hospital.

Successful clinical validation means PreciseInhale® could significantly reduce translational errors between research stages, reducing risk, costs and accelerating drug development.

ISAB CEO Manoush Masarrat: “The clinical validation of PreciseInhale® will potentially open up new markets valued in the billions of SEK. We’re delighted with reaching full enrollment on schedule and look forward to finalizing the study, as planned, before the end of the year.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.